BridgeBio secondary offering by KKR Genetic Disorder L.P. priced at $78.00 per share
BridgeBio Pharma will not receive proceeds as its selling stockholder offloads 5,000,000 shares in a deal expected to close August 17, 2026.
SEC filing
Latest
3 stories
Monday, August 17
Monday, August 10
BridgeBio reports Q2 2026 results as all three pipeline NDAs reach FDA review
BridgeBio said BBP-418 and encaleret now carry Priority Review PDUFA dates in November 2026 and May 2027, while infigratinib's achondroplasia NDA awaits a PDUFA date and a mid-2027 launch.
SEC filing
Wednesday, July 22
FDA accepts BridgeBio's NDA for encaleret in ADH1
The agency set a PDUFA target action date of May 8, 2027, and does not currently plan an advisory committee meeting.
SEC filing